Bernstein SocGen Group analyst Lee Hamnright reiterated an Outperform rating and $112.00 price target on Boston Scientific (NYSE: BSX).

The analyst commented: "Medtech stocks have struggled, and BSX has been the worst of the bunch, down ~35% from Sep 2025 highs on fears about intensifying PFA competition and a tricky setup in to the CHAMPION-AF readout (March 28) and Q1 earnings (~April 22). More broadly, U.S. Medtech has sharply lagged the market amid worries about weakness in Q1, potential margin pressures related to the Iran conflict, and a whole host of other issues.

We have a more favorable view of risk/reward here (+10%). If CHAMPION-AF hits, we think the stock could grind higher into Q1, perhaps up to $80. Having that important multiyear growth driver in your back pocket might help investors think about the Q1 setup a little differently. And on the downside, we have a hard time seeing BSX get down to a MDT multiple (15x), even if CHAMPION-AF fails. We believe there’s a good case to add here."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $70.17 yesterday.